Charmacy Pharmaceutical Co., Ltd. (HKG:2289)
Hong Kong
· Delayed Price · Currency is HKD 5.82
+0.01 (0.17%)
Apr 8, 2026, 3:46 PM HKT
Charmacy Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 4,329 | 4,385 | 4,348 | 4,141 | 3,763 | Upgrade
|
| Other Revenue | 55.3 | 50.34 | 56.11 | 34.61 | 30.55 | Upgrade
|
| Revenue | 4,385 | 4,435 | 4,404 | 4,175 | 3,794 | Upgrade
|
| Revenue Growth (YoY) | -1.15% | 0.72% | 5.47% | 10.06% | -4.96% | Upgrade
|
| Cost of Revenue | 4,045 | 4,115 | 4,115 | 3,907 | 3,560 | Upgrade
|
| Gross Profit | 339.88 | 320.88 | 288.38 | 268.61 | 234.12 | Upgrade
|
| Selling, General & Admin | 181.37 | 175.27 | 170 | 162.57 | 151.85 | Upgrade
|
| Other Operating Expenses | 9.44 | 10.33 | 9.3 | 10.07 | 8.13 | Upgrade
|
| Operating Expenses | 206.77 | 185.67 | 180.11 | 175.12 | 159.69 | Upgrade
|
| Operating Income | 133.11 | 135.21 | 108.28 | 93.49 | 74.42 | Upgrade
|
| Interest Expense | -56.83 | -62.46 | -41.93 | -35.07 | -41.52 | Upgrade
|
| Interest & Investment Income | 2.2 | 3.98 | 4.3 | 4.6 | 3.8 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.09 | -0.26 | -0.36 | -0.75 | 0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.21 | -3.6 | -4.11 | -6.99 | -4.01 | Upgrade
|
| EBT Excluding Unusual Items | 68.36 | 72.87 | 66.17 | 55.28 | 32.83 | Upgrade
|
| Impairment of Goodwill | - | -0.03 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.1 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.18 | 0.31 | 0.05 | 65.84 | 0.15 | Upgrade
|
| Asset Writedown | -3.87 | -0.33 | -0.01 | - | -0.01 | Upgrade
|
| Other Unusual Items | - | -1.62 | 1.32 | 0.94 | 0.01 | Upgrade
|
| Pretax Income | 64.31 | 71.19 | 67.42 | 122.05 | 32.98 | Upgrade
|
| Income Tax Expense | 18.04 | 17.91 | 16.07 | 31.58 | 9.83 | Upgrade
|
| Earnings From Continuing Operations | 46.27 | 53.28 | 51.34 | 90.47 | 23.15 | Upgrade
|
| Net Income | 46.27 | 53.28 | 51.34 | 90.47 | 23.15 | Upgrade
|
| Net Income to Common | 46.27 | 53.28 | 51.34 | 90.47 | 23.15 | Upgrade
|
| Net Income Growth | -13.16% | 3.78% | -43.25% | 290.76% | -42.91% | Upgrade
|
| Shares Outstanding (Basic) | 108 | 108 | 108 | 108 | 108 | Upgrade
|
| Shares Outstanding (Diluted) | 108 | 108 | 108 | 108 | 108 | Upgrade
|
| Shares Change (YoY) | -0.01% | -0.01% | 0.00% | 0.01% | -0.01% | Upgrade
|
| EPS (Basic) | 0.43 | 0.49 | 0.48 | 0.84 | 0.21 | Upgrade
|
| EPS (Diluted) | 0.43 | 0.49 | 0.48 | 0.84 | 0.21 | Upgrade
|
| EPS Growth | -13.15% | 3.79% | -43.25% | 290.72% | -42.90% | Upgrade
|
| Free Cash Flow | - | 90.31 | -137.39 | 35.46 | -44.58 | Upgrade
|
| Free Cash Flow Per Share | - | 0.84 | -1.27 | 0.33 | -0.41 | Upgrade
|
| Dividend Per Share | 0.300 | 0.450 | 0.300 | 0.450 | - | Upgrade
|
| Dividend Growth | -33.33% | 50.00% | -33.33% | - | - | Upgrade
|
| Gross Margin | 7.75% | 7.23% | 6.55% | 6.43% | 6.17% | Upgrade
|
| Operating Margin | 3.04% | 3.05% | 2.46% | 2.24% | 1.96% | Upgrade
|
| Profit Margin | 1.05% | 1.20% | 1.17% | 2.17% | 0.61% | Upgrade
|
| Free Cash Flow Margin | - | 2.04% | -3.12% | 0.85% | -1.18% | Upgrade
|
| EBITDA | 153.61 | 155.71 | 129.95 | 121.03 | 103.52 | Upgrade
|
| EBITDA Margin | 3.50% | 3.51% | 2.95% | 2.90% | 2.73% | Upgrade
|
| D&A For EBITDA | 20.5 | 20.5 | 21.68 | 27.54 | 29.09 | Upgrade
|
| EBIT | 133.11 | 135.21 | 108.28 | 93.49 | 74.42 | Upgrade
|
| EBIT Margin | 3.04% | 3.05% | 2.46% | 2.24% | 1.96% | Upgrade
|
| Effective Tax Rate | 28.05% | 25.16% | 23.84% | 25.87% | 29.80% | Upgrade
|
| Revenue as Reported | 4,385 | 4,435 | 4,404 | 4,175 | 3,794 | Upgrade
|
| Advertising Expenses | - | 6.08 | 11.52 | 8.89 | 9.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.